cas 68166-83-6|| where to buy (R)-tert-Butyl 2-hydroxypropanoate

Nombre del producto:(R)-tert-Butyl 2-hydroxypropanoate

IUPAC Name:tert-butyl (2R)-2-hydroxypropanoate

Unidad de embalaje	Stock disponible	Precio($)
CM166370-250mg	in stock	ȅȅ
CM166370-1g	in stock	ȤşǠ
CM166370-5g	1-2 Weeks	ǠȤƴŸ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 68166-83-6 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :68166-83-6; Fórmula molecular:C7H14O3; Punto de fusión:-; Código de sonrisas:C[C@@H](O)C(OC(C)(C)C)=O; Densidad:

: Número de catálogo:CM166370; Peso molecular:146.19; Punto de ebullición:; Nº Mdl:MFCD00191884; Almacenamiento:

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: NMD670; NMD Pharma A/S announces that it has dosed the first generalized myasthenia gravis patient in a Phase 2b clinical trial of NMD670, after receiving FDA IND clearance in March 2024 to conduct the study.
NMD670 is a first-in-class small molecule inhibitor of the skeletal muscle specific chloride ion channel (CIC-1). NMD Pharma has demonstrated that CIC-1 inhibition enhances weakened neuromuscular transmission and restores skeletal muscle function, and this novel treatment approach has demonstrated compelling preclinical and clinical data in animal models of myasthenia gravis, spinal muscular atrophy and a range of other neuromuscular disorders. NMD670 has also been granted orphan-drug designation by the U.S. FDA for treatment of gMG.